SPY761.43+1.53%QQQ694.35+2.90%BTC/USD74,431.94+1.00%DIA523.73+0.38%GLD365.89−0.94%TLT80.87−0.01%

Premium Services

Premium Services

ProKidney Corp

PROKNASDAQ

Trade with Public

Trade with Public

$1.15

0.0353.15%

Last update: Nov 11, 1:10 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

ProKidney (PROK) Stock Price Target 2026 & Analyst Forecast - Benzinga

ProKidney (PROK) Stock Price Target 2026

The average analyst price target for ProKidney is $6.43, 461.6% above the current price. Of 7 analysts, 5 rate it Buy, 1 Hold and 1 Sell. Targets range from $1 to $12. The latest change came on Oct 28, 2026, when Citigroup lowered its price target on ProKidney from $10 to $8 and kept a Buy rating.

The Average Analyst Price Target for ProKidney is $6.43.

Price Target Range — 8 Quarters

Analyst Consensus — 7 Analysts

5Buy

1Hold

1Sell

Consensus RatingBuy# Analysts7Avg. Consensus PT$6.43Upside to Avg. PT+461.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for ProKidney Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$10→$8
May 18, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$12
Dec 16, 2025	HC Wainwright & Co.	Joseph Pantginis	Initiate	Buy	$12
Jul 15, 2025	UBS	Eliana Merle	PT Raise	Buy	$4→$8
Jul 14, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$6→$7
Jul 9, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$6→$9
Jun 30, 2025	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$3→$1
Sep 30, 2024	JP Morgan	Anupam Rama	Initiate	Neutral	—
Sep 10, 2024	Guggenheim	Vamil Divan	Initiate	Buy	$6
Sep 4, 2024	B of A Securities	Jason Gerberry	PT Cut	Neutral	$4→$3
Jun 10, 2024	Jefferies	Kelly Shi	PT Cut	Buy	$15→$6
May 29, 2024	B of A Securities	Jason Gerberry	PT Raise	Neutral	$3→$4
Mar 7, 2024	Morgan Stanley	Judah Frommer	Assumes	Equal-Weight	$3
Jan 2, 2024	B of A Securities	Jason Gerberry	Downgrade	Buy→Neutral	$8→$2

Analyst Ratings News

PRO
Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8

Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.

Benzinga Newsdesk

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
UBS Maintains Buy on ProKidney, Raises Price Target to $8

UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.

Benzinga Newsdesk